Investing
Biotech firm Amyris files for bankruptcy in US
© Reuters.
(Reuters) – Biotech firm Amyris (NASDAQ:) Inc on Wednesday said it has filed for Chapter 11 bankruptcy in a U.S. court and is planning to sell its consumer brands to improve the company’s liquidity position.
Amyris said it has secured a $190 million financing commitment to support day-to-day operations, adding that its entities outside the U.S. are not included in the bankruptcy proceedings.
In a filing with the Delaware bankruptcy court, the company listed estimated assets in the range of $500 million to $1 billion and liabilities in the range of $1 billon to $10 billion.
“Restructuring is intended to improve the Company’s cost structure, capital structure, and liquidity position while streamlining Amyris’ business portfolio to focus on its core competencies in R&D…,” the company said.
In June, Amyris said it was cutting jobs to reduce costs and appointed Han Kieftenbeld as new interim CEO, following the resignation of John Melo.
Amyris had also initiated a “strategic transformation program” in June and secured a term loan facility of up to $50 million.
Read the full article here
-
Side Hustles4 days ago
Why the Best CEOs Think Like Anthropologists
-
Make Money5 days ago
Earn More in 2025: Top 10 High-Yield Savings Accounts Revealed
-
Passive Income5 days ago
How Pets Can Promote Better Health and Well-Being in the Workplace
-
Side Hustles5 days ago
10 Roles That Are Surprisingly Well-Suited for Outsourcing
-
Side Hustles5 days ago
What to Do If TikTok is Banned — How to Protect Your Brand
-
Make Money6 days ago
Build Your Future: 5 Simple Steps to Financial Stability
-
Side Hustles6 days ago
Meta Is Laying Off 5% of Its Workforce: Read the Memo
-
Investing2 days ago
TikTok faces US ban deadline as users brace for fallout By Reuters